Moving AI from pilot to GxP production

Pharma organizations are running dozens of successful AI pilots across R&D, but almost none have crossed into GxP production. Introducing non-deterministic AI into a regulated environment introduces complex validation burdens, fragmented vendor ecosystems, and hidden operational compute costs that stall deployment before it ever touches a clinical trial.

This playbook delivers an executive framework to price the true cost of bringing clinical AI to production, sequence your portfolio by feasibility and net value, and establish a defensible governance foundation.